Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Stomach Neoplasms 1Solid Tumors 1Solid Tumor 1Sarcoma, Synovial 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Nectin4-positive Advanced Malignant Solid Tumor 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid 1Glioma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1

Interventions

pembrolizumab 12Nivolumab 6atezolizumab 3Ipilimumab 3tislelizumab 2spartalizumab 2durvalumab 2avelumab 2Etoposide 2ruxolitinib 1poly ICLC 1obinutuzumab 1naptumomab estafenatox 1milademetan 1epacadostat 1enzalutamide 1entinostat 1cemiplimab 1budigalimab 1bemcentinib 1Thrombopoietin 1Sirolimus 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Levoleucovorin 1Leucovorin 1LY2940680 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Immunotherapy, Adoptive × Other solid neoplasm × Clear all
NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡